DTC
ITCI

Deep Track Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Deep Track Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,000,000
Closed -$264M – 76
2025
Q1 		$264M Hold
2,000,000
– – 8.54% 1
2024
Q4 		$167M Buy
2,000,000
+399,307
+25% +$32.8M 6.23% 3
2024
Q3 		$117M Buy
1,600,693
+62,771
+4% +$4.72M 3.72% 8
2024
Q2 		$105M Buy
1,537,922
+37,922
+3% +$2.63M 3.14% 11
2024
Q1 		$104M Sell
1,500,000
-500,000
-25% -$34.4M 2.97% 13
2023
Q4 		$143M Sell
2,000,000
-600,000
-23% -$34.5M 4.78% 3
2023
Q3 		$135M Buy
2,600,000
+1,051,748
+68% +$61.3M 5.23% 3
2023
Q2 		$98M Sell
1,548,252
-151,748
-9% -$9.46M 4.54% 7
2023
Q1 		$92.1M Buy
+1,700,000
New +$82.2M 3.78% 7

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Deep Track Capital's ITCI Position: Q2 2025 in Review

Deep Track Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,000,000 shares — an estimated $264M sold.

Deep Track Capital first reported a position in ITCI in Q1 2023 and held it in 9 quarters. The position peaked at $264M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Deep Track Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Deep Track Capital sold 2,000,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $264M.
  • Deep Track Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 9 quarters.
  • Deep Track Capital's Intra-Cellular Therapies Inc. position peaked at $264M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Deep Track Capital's 13F filing for Q2 2025, filed 14 Aug 2025.